CTLA-4 inhibitors can result in undisturbed T-cell activation to attack their target.[12] Ipilimumab, a CTLA-4 inhibitor, was the first checkpoint inhibitor approved for treating metastatic melanoma in 2011 after it showed improved overall survival compared with glycoprotein 100 peptide vaccine in patients with previously treated metastatic cutaneous melanoma.[28] There have been a few case reports in the literature about ipilimumab used in combination with anti-PD1 checkpoint inhibitors for the treatment of metastatic or locally advanced conjunctival melanoma [Figure 2A & 2B].[21]. Here, CTLA4 is linked to malignant conjunctival melanoma.